低危骨髓增生异常综合征的治疗选择  

Treatment options for low-risk myelodysplastic syndrome

作　　者：李莉娟[1] 马涛 张连生[1] LI Li-juan;MA Tao;ZHANG Lian-sheng(Department of Hematology,Key Laboratory of Hematology of Gansu Province,Lanzhou University Second Hospital,Lanzhou 730030,China)

机构地区：[1]兰州大学第二医院(第二临床医学院)血液科甘肃省血液病临床研究中心甘肃省血液病重点实验室,甘肃兰州730030

出　　处：《中国实用内科杂志》2022年第7期546-551,共6页Chinese Journal of Practical Internal Medicine

基　　金：国家血液系统疾病临床医学研究中心委托课题(2021WWA01);兰州市人才创新创业项目(2020-RC-48);兰州大学第二医院萃英科技创新项目(CY2017-ZD04,CY2019-MS14)。

摘　　要：骨髓增生异常综合征(MDS)是血液系统常见的克隆性造血疾病,按照预后积分系统可分为低危MDS和较高危MDS。高危患者主要采用去甲基化药物、化疗、异基因造血干细胞移植等方案。低危MDS患者的治疗主要以改善患者生活质量,识别高危转化风险为主,文章基于低危MDS治疗的进展,对其治疗选择的热点问题进行讨论。Myelodysplastic syndrome(MDS)is a common clonal hematopoietic disorder of the hematological system,which can be classified into low-risk MDS and high-risk MDS according to the prognostic score system.The main regimens used for high-risk MDS patients are demethylating drugs,chemotherapy,and allogeneic hematopoietic stem cell transplantation.The treatment of low-risk MDS patients is mainly focused on improving patients’quality of life and identifying the risk of high-risk conversion.This paper discusses the hot issues of treatment selection for low-risk MDS based on the new advances in treatments.

关 键 词：低危 骨髓增生异常综合征 治疗 选择 

分 类 号：R551.3[医药卫生—血液循环系统疾病]